Abstract:Meconium aspiration syndrome (MAS) is an important cause of respiratory distress in the term infant. Therapy for the disease remains problematic, and newer treatments such as high-frequency ventilation and inhaled nitric oxide are being applied with increasing frequency. There is a significant disturbance of the pulmonary surfactant system in MAS, with a wealth of experimental data indicating that inhibition of surfactant function in the alveolar space is an important element of the pathophysiology of the disease. This inhibition may be mediated by meconium, plasma proteins, haemoglobin and oedema fluid, and, at least in vitro, can be overcome by increasing surfactant phospholipid concentration. These observations have served as the rationale for administration of exogenous surfactant preparations in MAS, initially as standard bolus therapy and, more recently, in association with therapeutic lung lavage. Bolus surfactant therapy in ventilated infants with MAS has been found to improve oxygenation in most studies, although there are a significant proportion of nonresponders and in many cases the effect is transient. Pooled data from randomised controlled trials of surfactant therapy suggest a benefit in terms of a reduction in the requirement for extracorporeal membrane oxygenation (relative risk 0.48 in surfactant-treated infants) but no diminution of air leak or ventilator days. Current evidence would support the use of bolus surfactant therapy on a case by case basis in nurseries with a relatively high mortality associated with MAS, or the lack of availability of other forms of respiratory support such as high-frequency ventilation or nitric oxide. If used, bolus surfactant should be administered as early as practicable to infants who exhibit significant parenchymal disease, at a phospholipid dose of at least 100 mg/kg, rapidly instilled into the trachea. Natural surfactant or a third-generation synthetic surfactant should be used and the dosage repeated every 6 hours until oxygenation has improved. Lung lavage with dilute surfactant has recently emerged as an alternative to bolus therapy in MAS, which has the advantage of removing surfactant inhibitors from the alveolar space in addition to augmenting surfactant phospholipid concentration. Combined animal and human data suggest that lung lavage can remove significant amounts of meconium and alveolar debris, and thereby improve oxygenation and pulmonary mechanics. Arterial oxygen saturation inevitably falls during lavage but has been noted to recover relatively rapidly, even in infants with severe disease. Several randomised controlled trials of surfactant lavage in MAS are underway, and until the results are known, lavage must be considered an unproven and experimental therapy.

Chemiluminescence activity of phagocytes from tracheal aspirates of premature infants after surfactant therapy

Treatment of Severe Meconium Aspiration Syndrome with Porcine Surfactant: A Multicentre, Randomized, Controlled Trial

Surfactant Phospholipid Kinetics in Ventilated Children after Therapeutic Surfactant Supplementation

Gastric Aspirate Phosphatidylcholine Species in Preterm Neonates Receiving Aerosolized Surfactant

Early Immunomodulatory Effects of Different Natural Surfactant Preparations in Preterms With Respiratory Distress

Changes of respiratory system mechanics in ventilated lungs of preterm infants with two different schedules of surfactant treatment

Modified Protocols for Surfactant Therapy in Experimental Meconium Aspiration Syndrome

New Surfactant with SP-B and C Analogs Gives Survival Benefit after Inactivation in Preterm Lambs

Efficacy of synthetic surfactant (CHF5633) bolus and/or lavage in meconium-induced lung injury in ventilated newborn rabbits.

Efficacy of synthetic surfactant (CHF5633) bolus and/or lavage in meconium-induced lung injury in ventilated newborn rabbits

Suppression of Pulmonary Group B Streptococcal Proliferation and Translocation by Surfactants in Ventilated Near-Term Newborn Rabbits

Moving on from clinical animal-derived surfactants to peptide-based synthetic pulmonary surfactant

Beneficial Effect of Exogenous Surfactant in Infants Suffering Acute Respiratory Distress Syndrome after Cardiac Surgery.

Constrained drop surfactometry for studying adsorbed pulmonary surfactant at physiologically relevant high concentrations

Nebulised surfactant to reduce severity of respiratory distress: a blinded, parallel, randomised controlled trial

Regulation of Activity of Nuclear Factor-Kappab and Activator Protein-1 by Nitric Oxide, Surfactant and Glucocorticoids in Alveolar Macrophages from Piglets with Acute Lung Injury.

Neurological Function of Immature Babies After Surfactant Replacement Therapy

Characterization of phospholipid-modified lung surfactant in vitro and in a neonatal ARDS model reveals anti-inflammatory potential and surfactant lipidome signatures

The Inhibitory Effect of Curosurf® and Alveofact® on the Formation of Neutrophil Extracellular Traps

Surfactant therapy for meconium aspiration syndrome: current status

Early life surfactant protein-D levels in bronchoalveolar lavage fluids of extremely preterm neonates